Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans
Abstract Background Chagas disease (CD) is a tropical parasitic disease. Although the number of people infected is very high, the only drugs available to treat CD, nifurtimox (Nfx) and benznidazole, are highly toxic, particularly in the chronic stage of the disease. Coumarins are a large class of co...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Pharmacology and Toxicology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40360-019-0357-z |
id |
doaj-a1155bc5da654d5b82d957fc9d855049 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fabiana Gomes Nascimento Soares Gabriela Göethel Luciano Porto Kagami Gustavo Machado das Neves Elisa Sauer Estefania Birriel Javier Varela Itamar Luís Gonçalves Gilsane Von Poser Mercedes González Daniel Fábio Kawano Fávero Reisdorfer Paula Eduardo Borges de Melo Solange Cristina Garcia Hugo Cerecetto Vera Lucia Eifler-Lima |
spellingShingle |
Fabiana Gomes Nascimento Soares Gabriela Göethel Luciano Porto Kagami Gustavo Machado das Neves Elisa Sauer Estefania Birriel Javier Varela Itamar Luís Gonçalves Gilsane Von Poser Mercedes González Daniel Fábio Kawano Fávero Reisdorfer Paula Eduardo Borges de Melo Solange Cristina Garcia Hugo Cerecetto Vera Lucia Eifler-Lima Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans BMC Pharmacology and Toxicology Caenorhabditis elegans Trypanosoma cruzi Coumarins Chagas disease Structure-activity relationship |
author_facet |
Fabiana Gomes Nascimento Soares Gabriela Göethel Luciano Porto Kagami Gustavo Machado das Neves Elisa Sauer Estefania Birriel Javier Varela Itamar Luís Gonçalves Gilsane Von Poser Mercedes González Daniel Fábio Kawano Fávero Reisdorfer Paula Eduardo Borges de Melo Solange Cristina Garcia Hugo Cerecetto Vera Lucia Eifler-Lima |
author_sort |
Fabiana Gomes Nascimento Soares |
title |
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans |
title_short |
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans |
title_full |
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans |
title_fullStr |
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans |
title_full_unstemmed |
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans |
title_sort |
novel coumarins active against trypanosoma cruzi and toxicity assessment using the animal model caenorhabditis elegans |
publisher |
BMC |
series |
BMC Pharmacology and Toxicology |
issn |
2050-6511 |
publishDate |
2019-12-01 |
description |
Abstract Background Chagas disease (CD) is a tropical parasitic disease. Although the number of people infected is very high, the only drugs available to treat CD, nifurtimox (Nfx) and benznidazole, are highly toxic, particularly in the chronic stage of the disease. Coumarins are a large class of compounds that display a wide range of interesting biological properties, such as antiparasitic. Hence, the aim of this work is to find a good antitrypanosomal drug with less toxicity. The use of simple organism models has become increasingly attractive for planning and simplifying efficient drug discovery. Within these models, Caenorhabditis elegans has emerged as a convenient and versatile tool with significant advantages for the toxicological potential identification for new compounds. Methods Trypanocidal activity: Forty-two 4-methylamino-coumarins were assayed against the epimastigote form of Trypanosoma cruzi (Tulahuen 2 strain) by inhibitory concentration 50% (IC50). Toxicity assays: Lethal dose 50% (LD50) and Body Area were determined by Caenorhabditis elegans N2 strain (wild type) after acute exposure. Structure-activity relationship: A classificatory model was built using 3D descriptors. Results Two of these coumarins demonstrated near equipotency to Nifurtimox (IC50 = 5.0 ± 1 μM), with values of: 11 h (LaSOM 266), (IC50 = 6.4 ± 1 μM) and 11 g (LaSOM 231), (IC50 = 8.2 ± 2.3 μM). In C. elegans it was possible to observe that Nfx showed greater toxicity in both the LD50 assay and the evaluation of the development of worms. It is possible to observe that the efficacy between Nfx and the synthesized compounds (11 h and 11 g) are similar. On the other hand, the toxicity of Nfx is approximately three times higher than that of the compounds. Results from the QSAR-3D study indicate that the volume and hydrophobicity of the substituents have a significant impact on the trypanocidal activities for derivatives that cause more than 50% of inhibition. These results show that the C. elegans model is efficient for screening potentially toxic compounds. Conclusion Two coumarins (11 h and 11 g) showed activity against T. cruzi epimastigote similar to Nifurtimox, however with lower toxicity in both LD50 and development of C. elegans assays. These two compounds may be a feasible starting point for the development of new trypanocidal drugs. |
topic |
Caenorhabditis elegans Trypanosoma cruzi Coumarins Chagas disease Structure-activity relationship |
url |
https://doi.org/10.1186/s40360-019-0357-z |
work_keys_str_mv |
AT fabianagomesnascimentosoares novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT gabrielagoethel novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT lucianoportokagami novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT gustavomachadodasneves novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT elisasauer novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT estefaniabirriel novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT javiervarela novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT itamarluisgoncalves novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT gilsanevonposer novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT mercedesgonzalez novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT danielfabiokawano novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT faveroreisdorferpaula novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT eduardoborgesdemelo novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT solangecristinagarcia novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT hugocerecetto novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans AT veraluciaeiflerlima novelcoumarinsactiveagainsttrypanosomacruziandtoxicityassessmentusingtheanimalmodelcaenorhabditiselegans |
_version_ |
1724376739127230464 |
spelling |
doaj-a1155bc5da654d5b82d957fc9d8550492020-12-20T12:17:58ZengBMCBMC Pharmacology and Toxicology2050-65112019-12-0120S111310.1186/s40360-019-0357-zNovel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegansFabiana Gomes Nascimento Soares0Gabriela Göethel1Luciano Porto Kagami2Gustavo Machado das Neves3Elisa Sauer4Estefania Birriel5Javier Varela6Itamar Luís Gonçalves7Gilsane Von Poser8Mercedes González9Daniel Fábio Kawano10Fávero Reisdorfer Paula11Eduardo Borges de Melo12Solange Cristina Garcia13Hugo Cerecetto14Vera Lucia Eifler-Lima15Laboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulLaboratório Toxicologia/LATOX, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulFacultad de Ciencias-Facultad de Química, Universidad de la RepúblicaFacultad de Ciencias-Facultad de Química, Universidad de la RepúblicaLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulFacultad de Ciencias-Facultad de Química, Universidad de la RepúblicaFaculdade de Ciências Farmacêuticas, Universidade Estadual de CampinasUniversidade Estadual do Oeste do Paraná, Centro de Ciências Médicas e FarmacêuticasCentro de Ciências Médicas e Farmacêuticas, Universidade Estadual do Oeste do ParanáLaboratório Toxicologia/LATOX, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulFacultad de Ciencias-Facultad de Química, Universidad de la RepúblicaLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do SulAbstract Background Chagas disease (CD) is a tropical parasitic disease. Although the number of people infected is very high, the only drugs available to treat CD, nifurtimox (Nfx) and benznidazole, are highly toxic, particularly in the chronic stage of the disease. Coumarins are a large class of compounds that display a wide range of interesting biological properties, such as antiparasitic. Hence, the aim of this work is to find a good antitrypanosomal drug with less toxicity. The use of simple organism models has become increasingly attractive for planning and simplifying efficient drug discovery. Within these models, Caenorhabditis elegans has emerged as a convenient and versatile tool with significant advantages for the toxicological potential identification for new compounds. Methods Trypanocidal activity: Forty-two 4-methylamino-coumarins were assayed against the epimastigote form of Trypanosoma cruzi (Tulahuen 2 strain) by inhibitory concentration 50% (IC50). Toxicity assays: Lethal dose 50% (LD50) and Body Area were determined by Caenorhabditis elegans N2 strain (wild type) after acute exposure. Structure-activity relationship: A classificatory model was built using 3D descriptors. Results Two of these coumarins demonstrated near equipotency to Nifurtimox (IC50 = 5.0 ± 1 μM), with values of: 11 h (LaSOM 266), (IC50 = 6.4 ± 1 μM) and 11 g (LaSOM 231), (IC50 = 8.2 ± 2.3 μM). In C. elegans it was possible to observe that Nfx showed greater toxicity in both the LD50 assay and the evaluation of the development of worms. It is possible to observe that the efficacy between Nfx and the synthesized compounds (11 h and 11 g) are similar. On the other hand, the toxicity of Nfx is approximately three times higher than that of the compounds. Results from the QSAR-3D study indicate that the volume and hydrophobicity of the substituents have a significant impact on the trypanocidal activities for derivatives that cause more than 50% of inhibition. These results show that the C. elegans model is efficient for screening potentially toxic compounds. Conclusion Two coumarins (11 h and 11 g) showed activity against T. cruzi epimastigote similar to Nifurtimox, however with lower toxicity in both LD50 and development of C. elegans assays. These two compounds may be a feasible starting point for the development of new trypanocidal drugs.https://doi.org/10.1186/s40360-019-0357-zCaenorhabditis elegansTrypanosoma cruziCoumarinsChagas diseaseStructure-activity relationship |